Product

CAB-201

Aliases

CAB-201 following preconditioning with fludarabine and cyclophosphamide

1 clinical trial

4 indications

Indication

Idiopathic inflammatory myopathy

Indication

Dermatomyositis

Indication

Anti-Synthetase Syndrome

Indication

Immune-Mediated Necrotizing Myopathy

Clinical trial

A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Idiopathic Inflammatory Myopathy

Status: Recruiting, Estimated PCD: 2028-07-01